Disparate Effects of Stilbenoid Polyphenols on Hypertrophic Cardiomyocytes In Vitro vs. in the Spontaneously Hypertensive Heart Failure Rat

Stilbenoids are bioactive polyphenols, and resveratrol (trans-3,5,4′-trihydroxystilbene) is a representative stilbenoid that reportedly exerts cardioprotective actions. As resveratrol exhibits low oral bioavailability, we turned our attention to other stilbenoid compounds with a history of medicinal use and/or improved bioavailability. We determined the effects of gnetol (trans-3,5,2′,6′-tetrahydroxystilbene) and pterostilbene (trans-3,5-dimethoxy-4′-hydroxystilbene) on cardiac hypertrophy. In vitro, gnetol and pterostilbene prevented endothelin-1-induced indicators of cardiomyocyte hypertrophy including cell enlargement and protein synthesis. Gnetol and pterostilbene stimulated AMP-activated protein kinase (AMPK), and inhibition of AMPK, using compound C or shRNA knockdown, abolished these anti-hypertrophic effects. In contrast, resveratrol, gnetol, nor pterostilbene reduced blood pressure or hypertrophy in the spontaneously hypertensive heart failure (SHHF) rat. In fact, AMPK levels were similar between Sprague-Dawley and SHHF rats whether treated by stilbenoids or not. These data suggest that the anti-hypertrophic actions of resveratrol (and other stilbenoids?) do not extend to the SHHF rat, which models heart failure superimposed on hypertension. Notably, SHHF rat hearts exhibited prolonged isovolumic relaxation time (an indicator of diastolic dysfunction), and this was improved by stilbenoid treatment. In conclusion, stilbenoid-based treatment as a viable strategy to prevent pathological cardiac hypertrophy, a major risk factor for heart failure, may be context-dependent and requires further study.

[1]  P. Sachdev,et al.  Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease. , 2016, Current topics in medicinal chemistry.

[2]  Benedek Erdos,et al.  Age Impaired endothelium-dependent vasodilation is improved by resveratrol in rat mesenteric arteries , 2016, Journal of exercise nutrition & biochemistry.

[3]  Kazuki Nakamura,et al.  Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in a colon-26 tumor-bearing mouse model in vivo , 2015, Cancer medicine.

[4]  Hope D. Anderson,et al.  Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs , 2015, Phytotherapy research : PTR.

[5]  I. M. Robertson,et al.  Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. , 2015, Biochimica et biophysica acta.

[6]  Hope D. Anderson,et al.  Ligand Activation of Cannabinoid Receptors Attenuates Hypertrophy of Neonatal Rat Cardiomyocytes , 2014, Journal of cardiovascular pharmacology.

[7]  Jing Zhao,et al.  Preparation and Optimization of Resveratrol Nanosuspensions by Antisolvent Precipitation Using Box-Behnken Design , 2014, AAPS PharmSciTech.

[8]  F. Apple,et al.  Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats. , 2013, Toxicology and applied pharmacology.

[9]  Hope D. Anderson,et al.  Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats , 2013, Hypertension Research.

[10]  D. Mcfadden,et al.  Pterostilbene and cancer: current review. , 2012, The Journal of surgical research.

[11]  P. Netti,et al.  Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model , 2012, Diabetes.

[12]  Hope D. Anderson,et al.  Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. , 2011, European journal of pharmacology.

[13]  I. Kapetanovic,et al.  Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats , 2011, Cancer Chemotherapy and Pharmacology.

[14]  F. Villarroya,et al.  Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. , 2011, Cardiovascular research.

[15]  Hope D. Anderson,et al.  Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta. , 2011, Cardiovascular research.

[16]  A. Fenning,et al.  Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. , 2011, Current pharmaceutical biotechnology.

[17]  L. Bertrand,et al.  AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. , 2011, Cardiovascular research.

[18]  Fengjuan Yao,et al.  Metformin attenuates ventricular hypertrophy by activating the AMP‐activated protein kinase–endothelial nitric oxide synthase pathway in rats , 2011, Clinical and experimental pharmacology & physiology.

[19]  Hope D. Anderson,et al.  Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. , 2010, American journal of hypertension.

[20]  V. Dolinsky,et al.  Calorie Restriction Prevents Hypertension and Cardiac Hypertrophy in the Spontaneously Hypertensive Rat , 2010, Hypertension.

[21]  Yu-gang Dong,et al.  Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1 signaling pathway in vitro , 2010, Acta Pharmacologica Sinica.

[22]  T. Netticadan,et al.  Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. , 2010, The Journal of nutrition.

[23]  Hope D. Anderson,et al.  Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. , 2010, American journal of hypertension.

[24]  S. Javadov,et al.  Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway. , 2009, Journal of molecular and cellular cardiology.

[25]  K. Sunagawa,et al.  Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis , 2009, Hypertension Research.

[26]  Anita Y. M. Chan,et al.  Resveratrol Prevents the Prohypertrophic Effects of Oxidative Stress on LKB1 , 2009, Circulation.

[27]  F. Sakan,et al.  Stilbenoids isolated from the seeds of Melinjo (Gnetum gnemon L.) and their biological activity. , 2009, Journal of agricultural and food chemistry.

[28]  J. Cristol,et al.  Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. , 2008, Journal of agricultural and food chemistry.

[29]  U. Laufs,et al.  Metabolic Switch and Hypertrophy of Cardiomyocytes following Treatment with Angiotensin II Are Prevented by AMP-activated Protein Kinase* , 2008, Journal of Biological Chemistry.

[30]  B. Viollet,et al.  Resveratrol Inhibits Cardiac Hypertrophy via AMP-activated Protein Kinase and Akt* , 2008, Journal of Biological Chemistry.

[31]  Hope D. Anderson,et al.  Suppression of Cardiac Myocyte Hypertrophy by Conjugated Linoleic Acid , 2008, Journal of Biological Chemistry.

[32]  Y. Ohgami,et al.  Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity , 2008, Phytotherapy research : PTR.

[33]  T. Netticadan,et al.  Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. , 2007, American journal of physiology. Heart and circulatory physiology.

[34]  Dong Wang,et al.  Long‐term activation of adenosine monophosphate‐activated protein kinase attenuates pressure‐overload‐induced cardiac hypertrophy , 2007, Journal of cellular biochemistry.

[35]  V. Dolinsky,et al.  Role of AMP-activated protein kinase in healthy and diseased hearts. , 2006, American journal of physiology. Heart and circulatory physiology.

[36]  Joseph A. Baur,et al.  Therapeutic potential of resveratrol: the in vivo evidence , 2006, Nature Reviews Drug Discovery.

[37]  Mark A Sussman,et al.  The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits , 2006, Circulation research.

[38]  P. Pacaud,et al.  Rho kinases in cardiovascular physiology and pathophysiology. , 2006, Circulation research.

[39]  M. Drazner,et al.  Does load-induced ventricular hypertrophy progress to systolic heart failure? , 2005, American journal of physiology. Heart and circulatory physiology.

[40]  J. Bomser,et al.  Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. , 2005, American journal of physiology. Heart and circulatory physiology.

[41]  P. A. Oliver,et al.  A Scaleable Synthesis of Fiduxosin , 2004 .

[42]  Anita Y. M. Chan,et al.  Activation of AMP-activated Protein Kinase Inhibits Protein Synthesis Associated with Hypertrophy in the Cardiac Myocyte* , 2004, Journal of Biological Chemistry.

[43]  J. B. Magee,et al.  Resveratrol, pterostilbene, and piceatannol in vaccinium berries. , 2004, Journal of agricultural and food chemistry.

[44]  E. Olson,et al.  Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.

[45]  Yen-Ling Chen,et al.  Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[46]  Y. Akao,et al.  Effects of hydroxystilbene derivatives on tyrosinase activity. , 2003, Biochemical and biophysical research communications.

[47]  Tetsuro Ito,et al.  Phenolic constituents of Gnetum klossii. , 2003, Journal of natural products.

[48]  E. Blasi,et al.  Structural, functional, and molecular characterization of the SHHF model of heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.

[49]  Han-Dong Sun,et al.  Constituents of Gnetum montanum. , 2002, Fitoterapia.

[50]  L. Tesson,et al.  Stilbene content of mature Vitis vinifera berries in response to UV-C elicitation. , 2000, Journal of agricultural and food chemistry.

[51]  K. S. Huang,et al.  Stilbene dimers from the lianas of Gnetum hainanense. , 2000, Phytochemistry.

[52]  C. Charpentier,et al.  Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. , 1999, Journal of ethnopharmacology.

[53]  A. Gerdes,et al.  Myocyte remodeling during the progression to failure in rats with hypertension. , 1996, Hypertension.

[54]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.

[55]  K. Nakajima,et al.  Asymmetrical septal hypertrophy in patients with hypertension: A type of hypertensive left ventricular hypertrophy or hypertrophic cardiomyopathy combined with hypertension? , 1993, Clinical cardiology.

[56]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[57]  D. Gardner,et al.  Tissue-specific determinants of human atrial natriuretic factor gene expression in cardiac tissue. , 1989, The Journal of biological chemistry.

[58]  A. Zeidan,et al.  Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes , 2013, Molecular and Cellular Biochemistry.

[59]  A. Marian Contemporary treatment of hypertrophic cardiomyopathy. , 2009, Texas Heart Institute journal.

[60]  A. Means,et al.  Chutes and Ladders: the search for protein kinases that act on AMPK. , 2006, Trends in biochemical sciences.